SMAD2 and breast carcinoma: Administering FAKi and genetically rendering FAK deficient in breast cancer cells abrogated the interaction between TGFβRI and TGFβRII and thereby blocked phosphorylation of Smad2 and expression of its downstream effector PTHLH.